Table of Contents
The new report “Global Radiofrequency Ablation Devices Market Assessment & Forecast: 2015-2019” by Spearhead Acuity Business Research & Consulting Group reveals that North America lead the global radiofrequency ablation devices market with a share of 45.3% in 2014 that translated into revenues worth US$ 1,421.8 million.
North America leads the market primarily since the technology has had early commercial success in the region. Greater purchase power and availability to training and other modules enabled faster market penetration and awareness of RF ablation over the years. Today the RF technology is mature and well known among medical communities across the world and thus the growth rate for each region does not vary greatly from one another. Rising incidence of tumors, arrhythmia and chronic pain across the world continues to ensure that the market grows steadily. The American Academy of Pain Medicine and American Society of Anesthesiologists suggest that chronic pain affects over 60 million people across the world. Pain is experienced due to trauma, sensory or nervous disorders, cancer, aging and a host of other reasons making it one of the most lucrative segments for introducing medical device for treatment.
This report covers over 25 notable device manufacturers and highlights key players in each application segment while putting special emphasis on leaders of the RF ablation devices market such as Medtronic Inc (Covidien), Johnson & Johnson (Biosense Webster and DePuy Mitek), Boston Scientific, Stryker, St. Jude Medical, Arthrex and Haylard Health (former part of Kimberly Clark). Higher awareness of rarer applications such as endometrial ablation has also supplemented the growth of the RF ablation devices market in North America and Europe. Europe has shown particular resilience and leadership in approving renal denervation systems where the US FDA has remained unmovingly skeptical of the clinical outcomes. Nevertheless, the presence of most major RF technology companies in these regions and several new entrants in the market will ensure that these geographies continue to hold the controlling share. Growth is expected along with greater adoption of procedure planning and mapping systems such as Topera’s RhythmView and FIRMap that constitute capital equipment. A large number of catheter manufacturers are entering the market and provide catheters that are compatible with existing EP equipment.
Radiofrequency ablation was first applied in the medical field in 1930s when Krischner treated trigeminal neuralgia with thermocoagulation of the gassaerian ganglion. In the late 1950s the first commercial radiofrequency (RF) machine became available from Cosman and Aronow. Radiofrequency ablation uses RF waves to convert electromagnetic energy into heat energy which is dissipated into the tissue by an electrode/catheter/probe/ needle. In the following 70-80 years, RF ablation has found incredible applications in the treatment of various diseases and disorders that have already been covered in the report above. A large number of players are currently competing in the RF ablation market in different applications. Most players are inclined to strengthen existing portfolio of RF devices through distribution and acquisitions. Top RF device manufacturers extend their portfolio to address multiple applications such as tumor ablation, pain management together or focus on building portfolio of substitute products that address one medical condition. For e.g. St Jude Medical’s EP portfolio addresses arrhythmia by offering cardiac ablation and pacemakers. It addresses the pain management market through devices such as denervation system and neuromodulation for chronic pain. The market for devices that target a large population such as cardiac ablation, general surgery and cosmetology are now getting extremely crowded and it is expected that within a few years the overall market will become highly fragmented with private players that are unregulated and who have strong local dominance.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
“Medical Laboratory Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on growing. ...
“In Vitro Diagnostic Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on ...
“Clinical Diagnostic Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Date: April 3, 2017 Report Overview: A ...